OxTalks will soon be transitioning to Oxford Events (full details are available on the Staff Gateway). A two-week publishing freeze is expected in early Hilary to allow all events to be migrated to the new platform. During this period, you will not be able to submit or edit events on OxTalks. The exact freeze dates will be confirmed as soon as possible.
If you have any questions, please contact halo@digital.ox.ac.uk
The 2018 Nobel Prize announcement recognized the discovery of the “entirely new principle for cancer therapy” of negative immune regulation. It also cited the pharmaceutical industry’s lack of interest. Ultimately, a small biotech company developed both the anti-CTLA-4 antibody Yervoy/ipilimumab, based on James Allison’s work, and the anti-PD-1 antibody Opdivo/nivolumab based on Tasuku Honjo’s work. This talk will discuss why pharmaceutical companies were not interested, why these products were developed by the biotech company Medarex, and how this example highlights the results of new research into the origins of the most innovative medicines of the past two decades.
